| abstract |
The present invention provides a method for prognosing SCA in a subject, the method comprising determining plasma concentrations of MIF and Nt-ProBNP (or BNP) in a sample from the subject, diagnosing SCA when plasma concentrations of subject are superior to a baseline plasma MIF and Nt-proBNP (or BNP) concentration and the prognosis of SCA magnitude from the subject's plasma MIF and Nt-proBNP (or BNP) concentrations. The invention also relates to a device, a kit and a panel of cardiac biomarkers associated with SCA prognostic methods. |